# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates Generation Bio (NASDAQ:GBIO) with a Outperform and maintains $5 price target.
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $10 price target.
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0....
Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:GBIO) with a Buy and maintains $10 price target.
Wedbush analyst David Nierengarten reiterates Generation Bio (NASDAQ:GBIO) with a Outperform and maintains $5 price target.
Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0....
Data included in the posters describe iqDNA as a modified, structured, partially single-stranded DNA that evades innate immunit...